TY - JOUR
T1 - Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection
AU - Carter, Michael J.
AU - Fish, Matthew
AU - Jennings, Aislinn
AU - Doores, Katie J.
AU - Wellman, Paul
AU - Seow, Jeffrey
AU - Acors, Sam
AU - Graham, Carl
AU - Timms, Emma
AU - Kenny, Julia
AU - Neil, Stuart
AU - Malim, Michael H.
AU - Tibby, Shane M.
AU - Shankar-Hari, Manu
N1 - Funding Information:
We thank the parents and children who agreed to take part in this work. We thank J. Irons and the Evelina DIAMONDS Study team, the Evelina PIMS-TS Working Group and the Evelina Paediatric Research Team. We thank the flow cytometry core at the King’s College London (KCL) NIHR Biomedical Research Centre, and for logistical support we thank M. Brown, R. Ellis, S. Cochrane and C. Trouillet. We thank F. Krammer (Icahn School of Medicine at Mount Sinai) for provision of the RBD expression plasmid, P. Brouwer, M. van Gils and R. Sanders (University of Amsterdam) for the spike protein expression plasmid, and L. James, J. Luptak and L. Kiss (LMB, Cambridge) for the provision of purified nucleocapsid protein. The development of SARS-CoV-2 reagents (RBD) was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C. The study was supported by the King’s Together COVID-19 seed funds (M.J.C., M.S.H., K.J.D., S.N. and M.H.M.). M.J.C. is supported by a National Institute for Health Research (NIHR) Academic Clinical Lectureship. M.F. is supported by a National Institute of Academic Anesthesia BJA/RCoA fellowship (WKRO-2018-0047). A.J. is supported by PhD funds from the Critical Care Department at Guy’s and St Thomas’ Hospital. S.A. was supported by an MRC-KCL Doctoral Training Partnership in Biomedical Sciences Industrial Collaborative Award in Science and Engineering (iCASE) in partnership with Orchard Therapeutics (MR/R015643/1). C.G. is supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1). M.S.-H. is supported by the NIHR Clinician Scientist Award (CS-2016-16-011). The views expressed in this publication are those of the authors and not necessarily those of the NHS, NIHR or Department of Health and Social Care. This research was funded/supported by the NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and KCL and/or the NIHR Clinical Research Facility. The funding sources did not have any role in the design, conduct or interpretation of the study results.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2020/11
Y1 - 2020/11
N2 - Recent reports highlight a new clinical syndrome in children related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1—multisystem inflammatory syndrome in children (MIS-C)—which comprises multiorgan dysfunction and systemic inflammation2–13. We performed peripheral leukocyte phenotyping in 25 children with MIS-C, in the acute (n = 23; worst illness within 72 h of admission), resolution (n = 14; clinical improvement) and convalescent (n = 10; first outpatient visit) phases of the illness and used samples from seven age-matched healthy controls for comparisons. Among the MIS-C cohort, 17 (68%) children were SARS-CoV-2 seropositive, suggesting previous SARS-CoV-2 infections14,15, and these children had more severe disease. In the acute phase of MIS-C, we observed high levels of interleukin-1β (IL-1β), IL-6, IL-8, IL-10, IL-17, interferon-γ and differential T and B cell subset lymphopenia. High CD64 expression on neutrophils and monocytes, and high HLA-DR expression on γδ and CD4+CCR7+ T cells in the acute phase, suggested that these immune cell populations were activated. Antigen-presenting cells had low HLA-DR and CD86 expression, potentially indicative of impaired antigen presentation. These features normalized over the resolution and convalescence phases. Overall, MIS-C presents as an immunopathogenic illness1 and appears distinct from Kawasaki disease.
AB - Recent reports highlight a new clinical syndrome in children related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1—multisystem inflammatory syndrome in children (MIS-C)—which comprises multiorgan dysfunction and systemic inflammation2–13. We performed peripheral leukocyte phenotyping in 25 children with MIS-C, in the acute (n = 23; worst illness within 72 h of admission), resolution (n = 14; clinical improvement) and convalescent (n = 10; first outpatient visit) phases of the illness and used samples from seven age-matched healthy controls for comparisons. Among the MIS-C cohort, 17 (68%) children were SARS-CoV-2 seropositive, suggesting previous SARS-CoV-2 infections14,15, and these children had more severe disease. In the acute phase of MIS-C, we observed high levels of interleukin-1β (IL-1β), IL-6, IL-8, IL-10, IL-17, interferon-γ and differential T and B cell subset lymphopenia. High CD64 expression on neutrophils and monocytes, and high HLA-DR expression on γδ and CD4+CCR7+ T cells in the acute phase, suggested that these immune cell populations were activated. Antigen-presenting cells had low HLA-DR and CD86 expression, potentially indicative of impaired antigen presentation. These features normalized over the resolution and convalescence phases. Overall, MIS-C presents as an immunopathogenic illness1 and appears distinct from Kawasaki disease.
UR - http://www.scopus.com/inward/record.url?scp=85089489604&partnerID=8YFLogxK
U2 - 10.1038/s41591-020-1054-6
DO - 10.1038/s41591-020-1054-6
M3 - Article
C2 - 32812012
AN - SCOPUS:85089489604
SN - 1078-8956
VL - 26
SP - 1701
EP - 1707
JO - Nature Medicine
JF - Nature Medicine
IS - 11
ER -